Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genmab A/S ADR (NQ: GMAB ) 26.95 -0.26 (-0.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Genmab A/S ADR < Previous 1 2 3 4 5 6 7 8 9 Next > Genmab Announces Changes to its Executive Committee August 16, 2024 From Genmab A/S Via Business Wire On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session August 13, 2024 Via Benzinga GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 August 08, 2024 GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products August 05, 2024 BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... Via Benzinga Exposures COVID-19 Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? August 05, 2024 Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. Via Chartmill What 8 Analyst Ratings Have To Say About Genmab August 01, 2024 Via Benzinga What 8 Analyst Ratings Have To Say About Genmab July 15, 2024 Via Benzinga While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. August 05, 2024 While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. Via Chartmill Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. July 15, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. Via Chartmill NASDAQ:GMAB, an undervalued stock with good fundamentals. July 01, 2024 GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma June 28, 2024 From Genmab A/S Via Business Wire AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway June 27, 2024 The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. Via Benzinga Exposures Product Safety 10 Analysts Assess Genmab: What You Need To Know June 20, 2024 Via Benzinga What 9 Analyst Ratings Have To Say About Genmab May 20, 2024 Via Benzinga EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) June 26, 2024 From Genmab A/S Via Business Wire 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Despite its growth, NASDAQ:GMAB remains within the realm of affordability. June 21, 2024 Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 7 Stocks That Could Safely 10X by 2030 June 06, 2024 Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. Via InvestorPlace NASDAQ:GMAB is showing good growth, while it is not too expensive. May 02, 2024 Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB). Via Chartmill Decoding 9 Analyst Evaluations For Genmab April 30, 2024 Via Benzinga Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) June 03, 2024 From Genmab A/S Via Business Wire Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma June 02, 2024 From Genmab A/S Via Business Wire Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) June 01, 2024 From Genmab A/S Via Business Wire Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session May 24, 2024 Via Benzinga Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Genmab A/S Via Business Wire Genmab Completes Acquisition of ProfoundBio May 21, 2024 From Genmab A/S Via Business Wire 7 Biotech Stocks That Could Breathe New Life Into Your Portfolio May 20, 2024 Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. Via InvestorPlace Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress May 14, 2024 From Genmab A/S Via Business Wire GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024 May 02, 2024 GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer April 29, 2024 From Genmab A/S Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.